Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and is one of the
leading causes of cancer-related death among American men. Therefore, detection of …

Approximately 20% of invasive breast cancers have upregulation/gene amplification of the
oncogene human epidermal growth factor receptor-2 (HER2/ErbB2). Of these, some also …

Simple Summary α6β4-integrins and plectin are the key structural components of
hemidesmosomes that have been implicated in carcinogenesis and which are thus …

Suppression of androgen receptor (AR) activity in prostate cancer by androgen depletion or
direct AR antagonist treatment, although initially effective, leads to incurable castration …

Background/Aim: Head-and-neck squamous cell carcinoma (HNSCC) is the fifth most
common cancer in the world and human papillomavirus (HPV) is an important risk factor for …

Abstract Phosphorylation of serine 81 (pS81) in the N-terminal transactivation domain of the
androgen receptor (AR) has been linked to its transcriptional activation in prostate cancer …

Prostate cancer has a relatively good prognosis, but most cases develop resistance to
hormone therapy, leading to castration-resistant prostate cancer (CRPC). Androgen receptor …

LRIG1 has been reported to be a tumor suppressor in gastrointestinal tract and epidermis.
However, little is known about the expression, regulation and biological functions of LRIG1 …

Background Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in
castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual …

Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the
second leading cause of cancer-related deaths in US men. Most of these deaths are …